122
Participants
Start Date
September 25, 2025
Primary Completion Date
September 25, 2027
Study Completion Date
September 25, 2028
Ruxolitinib (JAKAVI®)
Ruxolitinib will be administered orally at a dose of 10 mg twice daily (approximately every 12 hours), with or without food. Dose modifications are allowed according to protocol-defined safety and efficacy criteria. Ruxolitinib may be continued for up to 24 weeks, with tapering guided by patient response and GVHD status.
Etanercept (Enbrel)
Etanercept will be administered as a subcutaneous injection at a dose of 25 mg twice weekly for 4 weeks (total 8 doses). For patients with partial response at day 28, treatment may be extended once weekly for an additional 2-4 weeks at the investigator's discretion.
RECRUITING
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
The First Affiliated Hospital of Zhengzhou University
OTHER
Tongji Hospital
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
The Children's Hospital of Zhejiang University School of Medicine
OTHER
Ruijin Hospital
OTHER
First Affiliated Hospital of Zhejiang University
OTHER